1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
2.
|
Williams CS, Tsujii M, Reese J, Dey SK and
DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin
Invest. 105:1589–1594. 2000. View
Article : Google Scholar : PubMed/NCBI
|
3.
|
Rodrigues S, Bruyneel E, Rodrigue CM,
Shahin E and Gespach C: Cyclooxygenase 2 and carcinogenesis. Bull
Cancer. 91(Suppl 2): S61–S76. 2004.(In French).
|
4.
|
Murakami M, Taketomi Y, Sato H and
Yamamoto K: Secreted phospholipase A2 revisited. J Biochem.
150:233–255. 2011. View Article : Google Scholar
|
5.
|
Lambeau G and Gelb MH: Biochemistry and
physiology of mammalian secreted phospholipases A2. Annu Rev
Biochem. 77:495–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Touqui L and Wu YZ: Interaction of
secreted phospholipase A2 and pulmonary surfactant and its
pathophysiological relevance in acute respiratory distress
syndrome. Acta Pharmacol Sin. 24:1292–1296. 2003.PubMed/NCBI
|
7.
|
Triggiani M, Granata F, Frattini A and
Marone G: Activation of human inflammatory cells by secreted
phospholipases A2. Biochim Biophys Acta. 1761:1289–1300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8.
|
Nevalainen TJ, Graham GG and Scott KF:
Antibacterial actions of secreted phospholipases A2. Review.
Biochim Biophys Acta. 1781:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Hanasaki K, Ono T, Saiga A, et al:
Purified group X secretory phospholipase A(2) induced prominent
release of arachidonic acid from human myeloid leukemia cells. J
Biol Chem. 274:34203–34211. 1999. View Article : Google Scholar
|
10.
|
Murakami M, Kambe T, Shimbara S, et al:
Different functional aspects of the group II subfamily (Types IIA
and V) and type X secretory phospholipase A(2)s in regulating
arachidonic acid release and prostaglandin generation. Implications
of cyclooxygenase-2 induction and phospholipid scramblase-mediated
cellular membrane perturbation. J Biol Chem. 274:31435–31444.
1999.
|
11.
|
Morioka Y, Ikeda M, Saiga A, et al:
Potential role of group X secretory phospholipase A(2) in
cyclooxygenase-2-dependent PGE(2) formation during colon
tumorigenesis. FEBS Lett. 487:262–266. 2000. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Surrel F, Jemel I, Boilard E, et al: Group
X phospholipase A2 stimulates the proliferation of colon cancer
cells by producing various lipid mediators. Mol Pharmacol.
76:778–790. 2009. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Mounier CM, Wendum D, Greenspan E, Fléjou
JF, Rosenberg DW and Lambeau G: Distinct expression pattern of the
full set of secreted phospholipases A2 in human colorectal
adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer.
98:587–595. 2008. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Tribler L, Jensen LT, Jørgensen K, et al:
Increased expression and activity of group IIA and X secretory
phospholipase A2 in peritumoral versus central colon carcinoma
tissue. Anticancer Res. 27:3179–3185. 2007.PubMed/NCBI
|
15.
|
Degousee N, Ghomashchi F, Stefanski E, et
al: Groups IV, V, and X phospholipases A2s in human neutrophils:
role in eicosanoid production and gram-negative bacterial
phospholipid hydrolysis. J Biol Chem. 277:5061–5073. 2002.
View Article : Google Scholar : PubMed/NCBI
|
16.
|
Masuda S, Murakami M, Matsumoto S, et al:
Localization of various secretory phospholipase A2 enzymes in male
reproductive organs. Biochim Biophys Acta. 1686:61–76. 2004.
View Article : Google Scholar : PubMed/NCBI
|
17.
|
Murakami M, Taketomi Y, Miki Y, Sato H,
Hirabayashi T and Yamamoto K: Recent progress in phospholipase
A2 research: from cells to animals to humans. Prog Lipid
Res. 50:152–192. 2011.
|
18.
|
Murakami M, Masuda S, Shimbara S, Ishikawa
Y, Ishii T and Kudo I: Cellular distribution, post-translational
modification, and tumorigenic potential of human group III secreted
phospholipase A(2). J Biol Chem. 280:24987–24998. 2005. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Yamashita S, Yamashita J, Sakamoto K, et
al: Increased expression of membrane-associated phospholipase A2
shows malignant potential of human breast cancer cells. Cancer.
71:3058–3064. 1993. View Article : Google Scholar
|
20.
|
Yamashita S, Yamashita J and Ogawa M:
Overexpression of group II phospholipase A2 in human breast cancer
tissues is closely associated with their malignant potency. Br J
Cancer. 69:1166–1170. 1994. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Kiyohara H, Egami H, Kako H, et al:
Immunohistochemical localization of group II phospholipase A2 in
human pancreatic carcinomas. Int J Pancreatol. 13:49–57.
1993.PubMed/NCBI
|
22.
|
Jiang J, Neubauer BL, Graff JR, et al:
Expression of group IIA secretory phospholipase A2 is elevated in
prostatic intraepithelial neoplasia and adenocarcinoma. Am J
Pathol. 160:667–671. 2002. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Dong Q, Patel M, Scott KF, Graham GG,
Russell PJ and Sved P: Oncogenic action of phospholipase A2 in
prostate cancer. Cancer Lett. 240:9–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Ying Z, Tojo H, Komatsubara T, et al:
Enhanced expression of group II phospholipase A2 in human
hepatocellular carcinoma. Biochim Biophys Acta. 1226:201–205. 1994.
View Article : Google Scholar : PubMed/NCBI
|
25.
|
Leung SY, Chen X, Chu KM, et al:
Phospholipase A2 group IIA expression in gastric adenocarcinoma is
associated with prolonged survival and less frequent metastasis.
Proc Natl Acad Sci USA. 99:16203–16208. 2002. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Xing XF, Li H, Zhong XY, et al:
Phospholipase A2 group IIA expression correlates with prolonged
survival in gastric cancer. Histopathology. 59:198–206.
2011.PubMed/NCBI
|
27.
|
Buhmeida A, Bendardaf R, Hilska M, et al:
PLA2 (group IIA phospholipase A2) as a prognostic determinant in
stage II colorectal carcinoma. Ann Oncol. 20:1230–1235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
28.
|
Kashiwagi M, Friess H, Uhl W, et al: Group
II and IV phospholipase A(2) are produced in human pancreatic
cancer cells and influence prognosis. Gut. 45:605–612. 1999.
View Article : Google Scholar : PubMed/NCBI
|
29.
|
Ganesan K, Ivanova T, Wu Y, et al:
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a
novel beta-catenin/TCF target gene. Cancer Res. 68:4277–4286. 2008.
View Article : Google Scholar : PubMed/NCBI
|
30.
|
Graff JR, Konicek BW, Deddens JA, et al:
Expression of group IIa secretory phospholipase A2 increases with
prostate tumor grade. Clin Cancer Res. 7:3857–3861. 2001.PubMed/NCBI
|
31.
|
Chan TA, Morin PJ, Vogelstein B and
Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory
drug-mediated apoptosis. Proc Natl Acad Sci USA. 95:681–686. 1998.
View Article : Google Scholar : PubMed/NCBI
|
32.
|
Reddy BS: Chemoprevention of colon cancer
by dietary fatty acids. Cancer Metastasis Rev. 13:285–302. 1994.
View Article : Google Scholar : PubMed/NCBI
|
33.
|
Bendardaf R, Lamlum H, Ristämaki R,
Korkeila E, Syrjänen K and Pyrhönen S: Mismatch repair status is a
predictive factor of tumour response to 5-fluorouracil and
irinotecan chemotherapy in patients with advanced colorectal
cancer. Tumour Biol. 28:212–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
34.
|
Bendardaf R, Lamlum H, Ristamäki R,
Korkeila E, Syrjänen K and Pyrhönen S: Thymidylate synthase and
microsatellite instability in colorectal cancer: implications for
disease free survival, treatment response and survival with
metastases. Acta Oncol. 47:1046–1053. 2008. View Article : Google Scholar : PubMed/NCBI
|
35.
|
Cummings BS: Phospholipase A2 as targets
for anti-cancer drugs. Biochem Pharmacol. 74:949–959. 2007.
View Article : Google Scholar : PubMed/NCBI
|